4//SEC Filing
Carney William J 4
Accession 0001209191-12-003890
CIK 0001301081other
Filed
Jan 16, 7:00 PM ET
Accepted
Jan 17, 5:09 PM ET
Size
21.9 KB
Accession
0001209191-12-003890
Insider Transaction Report
Form 4
Pharmasset IncVRUS
Carney William J
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−20,000→ 0 totalExercise: $6.84Exp: 2017-10-10→ Common Stock (20,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−6,666.67→ 0 totalExercise: $3.38Exp: 2014-03-15→ Common Stock (6,666.67 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−40,000→ 0 totalExercise: $9.30Exp: 2018-10-29→ Common Stock (40,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−40,000→ 0 totalExercise: $10.83Exp: 2019-10-14→ Common Stock (40,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−20,000→ 0 totalExercise: $10.10Exp: 2018-07-16→ Common Stock (20,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−40,000→ 0 totalExercise: $16.17Exp: 2020-10-14→ Common Stock (40,000 underlying) - Disposition from Tender
Common Stock
2012-01-12$137.00/sh−146,330$20,047,210→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−15,000→ 0 totalExercise: $83.52Exp: 2021-10-11→ Common Stock (15,000 underlying)
Footnotes (8)
- [F1]Includes 17,000 shares of time vesting restricted stock, reflecting the two-for-one stock split of the Issuer's common stock effective August 31, 2011 (the "Split"), which became unrestricted and eligible for tender pursuant to the Agreement and Plan of Merger between the Issuer and Gilead Sciences, Inc. (the "Merger Agreement").
- [F2]These options, which reflect the Split and which vested on the first anniversary of the date of grant (March 15, 2004), were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $133.62 per share, representing the difference between the exercise price of the options and $137.00 per share.
- [F3]These options, which reflect the Split and which vested as to 25% on the date of grant (October 10, 2007), as to 25% on the first anniversary thereof, and as to an additional 6.25% quarterly thereafter for the following two years, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $130.16 per share, representing the difference between the exercise price of the options and $137.00 per share.
- [F4]These options, which reflect the Split and which vested to 25% on the date of grant (July 16, 2008), as to 25% on the first anniversary thereof, and as to an additional 6.25% quarterly thereafter for the following two years, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $126.90 per share, representing the difference between the exercise price of the options and $137.00 per share.
- [F5]These options, which reflect the Split and which vested as to 25% on the date of grant (October 29, 2008), as to 25% on the first anniversary thereof, and as to an additional 6.25% quarterly thereafter for the following two years, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $127.70 per share, representing the difference between the exercise price of the options and $137.00 per share.
- [F6]These options, which reflect the Split and which provided for vesting as to 25% on the date of grant (October 14, 2009), as to 25% on the first anniversary thereof, and as to an additional 6.25% quarterly thereafter for the following two years, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $126.17 per share, representing the difference between the exercise price of the options and $137.00 per share.
- [F7]These options, which reflect the Split and which provided for vesting as to 25% on the date of grant (October 14, 2010), as to 25% on the first anniversary thereof, and as to an additional 6.25% quarterly thereafter for the following two years, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $120.83 per share, representing the difference between the exercise price of the options and $137.00 per share.
- [F8]These options, which provided for vesting as to 25% on the date of grant (October 11, 2011), as to 25% on the first anniversary thereof, and as to an additional 6.25% quarterly thereafter for the following two years, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $53.48 per share, representing the difference between the exercise price of the options and $137.00 per share.
Documents
Issuer
Pharmasset Inc
CIK 0001301081
Entity typeother
Related Parties
1- filerCIK 0001397455
Filing Metadata
- Form type
- 4
- Filed
- Jan 16, 7:00 PM ET
- Accepted
- Jan 17, 5:09 PM ET
- Size
- 21.9 KB